Editas Medicine (EDIT)

$32.80 1.51 (4.83%)

16:00 EDT EDIT Stock Quote Delayed 30 Minutes

7 Stocks to Buy for May

By Tezcan Gecgil, InvestorPlace Contributor Apr 27, 2021

Broader markets be at all-time highs, but there are still opportunities for the coming months. Here are seven stocks to buy this May.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

Goldman Sachs Just Put Editas Stock on Sale — Buy the Dip

More Articles

Volume:

Previous Close -

Market Cap 2.22B

PE Ratio -9.48

EPS -3.46

Volume (Avg. Vol.) 1.78M

Day's Range 29.35 - 33.35

52-Week Range 23.51 - 99.95

Dividend & Yield N/A (N/A)

EDIT Stock Predictions, Articles, and Editas Medicine News

From InvestorPlace
From the Web

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

By Luke Lango, InvestorPlace Senior Investment Analyst Apr 15, 2021

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today

By William White, InvestorPlace Writer Mar 10, 2021

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players.

A Play on the Biggest Scientific Breakthrough of the Century

By Luke Lango, InvestorPlace Senior Investment Analyst Jan 22, 2021

There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT).

7 CRISPR Stocks for the Future of Medicine

By Luke Lango, InvestorPlace Senior Investment Analyst Jan 15, 2021

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.

Editas Medicine: 6 Things for Potential EDIT Stock Investors to Know Today

By William White, InvestorPlace Writer Dec 21, 2020

Editas Medicine (EDIT) stock is soaring higher on Monday with heavy trading despite a lack of recent news from the gene-editing company.

5 Disruptive Biotech Stocks to Buy for the Future That Is Here

By Alex Sirois Aug 13, 2020

Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.

7 Biotech Stocks to Buy and Hold in 2020

By Chris Lau, InvestorPlace Contributor Mar 16, 2020

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

The Top 3 Gene-Editing Stocks to Own in 2020

By Ian Cooper Mar 11, 2020

The gene-editing revolution is already here, and could be a sizable boon for investors in three of the sector's top stocks.

3 Biotech Stocks That Are Set for a Breakthrough

By Matt McCall, Editor, MoneyWire Feb 1, 2019

If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.

Gene Editing is a Major Technology to Watch

By Matt McCall, Editor, MoneyWire Aug 27, 2018

Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.

Whole Foods Market, Inc. (WFM) and Xtant Medical Holdings Inc (XTNT) Lead 13 Activist Investment Filings

By Fintel May 31, 2017

13G and 13D filings are windows into activist investor activity. Latest filings include Whole Foods Markets, Inc., and these 12 other stocks

First Week of June 18th Options Trading For Editas Medicine (EDIT)

From Market News Video May 11, 2021

Investors in Editas Medicine Inc (EDIT) saw new options become available this week, for the June 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new June 18th contracts and identified one put and one call contract of particular interest.

Editas Medicine Enters Oversold Territory (EDIT)

From Market News Video May 10, 2021

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript

From The Motley Fool May 5, 2021

EDIT earnings call for the period ending March 31, 2021.

What Really Mattered With Editas Medicine's Q1 Update

From The Motley Fool May 5, 2021

It wasn't the biotech's financial performance.

A Trigger to Get Long: Three Inside Up, RSI, Moving Average Trigger in Editas Medicine Inc

From Capital Market Laboratories Apr 26, 2021

The Techncial Trigger Driven Stock Trade in Editas Medicine Inc (NASDAQ:EDIT) .

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues

From Benzinga May 5, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...